) recently announced that results from the CORE II clinical study
were published in the journal
. The study, conducted in Europe, Australia, Israel and Russia,
is one of the main phase III programs evaluating Uceris extended
release tablet in patients suffering from active, mild to
moderate ulcerative colitis.
Results showed that the 9 mg dose of Uceris had a
statistically significant benefit over placebo in meeting the
primary endpoint. The primary endpoint was the induction of
combined clinical and endoscopic remission at week 8 in patients
with active, mild to moderate ulcerative colitis.
Uceris 9 mg was found to be well tolerated by the patients.
The adverse events observed in the Uceris 9 mg arm were similar
to placebo. No important clinical differences were found between
Uceris and placebo in relation to glucocorticoid-related
We remind investors that on Jan 14, 2013, Uceris 9 mg received
approval from the US Food and Drug Administration (FDA) for the
induction of remission in patients with active, mild to moderate
ulcerative colitis. The product was launched in the US in Feb
Santarus is focused on the commercialization of Uceris and is
promoting the product to gastroenterologists, endocrinologists
and other selected physicians.
We remind investors that companies like
Salix Pharmaceuticals Ltd
) have a presence in the ulcerative colitis market.
Santarus currently carries a Zacks Rank #3 (Hold). Meanwhile,
Array BioPharma, Inc.
) looks well-positioned in the biopharma space. Array BioPharma
carries a Zacks Rank #2 (Buy).
ARRAY BIOPHARMA (ARRY): Free Stock Analysis
ASTRAZENECA PLC (AZN): Free Stock Analysis
SALIX PHARM-LTD (SLXP): Free Stock Analysis
SANTARUS INC (SNTS): Free Stock Analysis
To read this article on Zacks.com click here.